Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunológikumok a felidae, - macskák - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. a immunitásra való hajlamot 1 héttel a rhinotracheitis, calicivírus és chlamydophila felis komponensek. az immunitás időtartama az utolsó (újra) oltás után egy év.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunológikumok a felidae, - macskák - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunológikumok a felidae, - macskák - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. a immunitást a rhinotracheitis, a kalicavírus, a chlamydophila felis és a panleucopenia komponensek elsődleges immunizálás után egy héttel igazolták. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunológikumok a felidae, - macskák - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - legfeljebb három, a következő tisztított, inaktivált, láb -, illetve-száj betegség vírus törzsek: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o tajvan 3/97 ≥ 6 pd50*; a22 iraki ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; pulyka 14/98 ≥ 6 pd50*; Ázsia 1 shamir ≥ 6 pd50*; szo2 szaúd-arábia ≥ 6 pd50*; * pd50 – 50% - a védő adag marha leírt ph eur. monográfia 0063. - immunológikumok - pigs; cattle; sheep - a szarvasmarhák, a juhok és a sertések 2 hetes aktív immunizálása a ragadós száj- és körömfájás ellen a klinikai tünetek csökkentése érdekében.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

zoetis belgium sa - sertés cirkovírus rekombináns vírus (cpcv) 1-2 inaktivált - immunológikumok - sertés (malac) - aktív immunizálására a disznók éves kor felett három héttel ellen-es típusú sertés circovírus 2 (pcv2), hogy csökkentse a vírusterhelés vér lymphoid szövetekben, de az elváltozások a lymphoid szövetekben kapcsolódó pcv2-fertőzés, valamint a klinikai tünetek csökkentése érdekében - beleértve a veszteség a napi súlygyarapodás, a halandóság társul utáni elválasztás multisystemic pazarlás szindróma.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sertés - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - a vakcinák - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - immunológikumok - sheep; cattle - sheepactive a kéknyelv-betegség elleni immunizáció szerotípusa 8, hogy megakadályozzák a viraemia, valamint a klinikai tünetek csökkentésére. az immunitás kialakulása: 20 nappal a második adag után. a mentesség időtartama: a második adag után 1 év. cattleactive a kéknyelv-betegség elleni immunizáció szerotípusa 8, hogy megakadályozzák a viraemia. a védettség kezdete: 31 nappal a második adag után. a mentesség időtartama: a második adag után 1 év.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

mérial - kéknyelv-betegség-szerotípusa-2 antigén, kéknyelv-betegség-szerotípusa-4 antigén - kéknyelv-betegség vírus, inaktivált vírust tartalmazó vakcinát, immunológikumok a ovidae - juh - a juhok aktív immunizálása a viremia megelőzésére és a kéknyelv-betegség vírus 2-es és 4-es szerotípusai által okozott klinikai tünetek csökkentésére.